Journals / Turkish journal of nephrology (Online) / 2020 / Cilt: 29 - Sayı: 1

Lupus Nephritis Presenting with Preeclampsia

Pages
84–88
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

While SLE is a risk factor for preeclampsia, LN should be considered in kidney failure in the third trimester or postpartum period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multisystem involvement.
📊
Key Findings & Data:However preeclampsia rarely occurs within 48 h of postpartum.
💡
Conclusion & Impact:While SLE is a risk factor for preeclampsia, LN should be considered in kidney failure in the third trimester or postpartum period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multisystem involvement. The renal involvement of SLE may present with hematuria , proteinuria or acute kidney dysfunction. It is well established that pregnancy may trigger the disease activation in patients with SLE. Lupus nephritis (LN) may be diagnosed during pregnancy in very few patients. Preeclampsia is a pregnancy-related disorder characterized by maternal hypertension, proteinuria, and edema and is sometimes complicated by renal dysfunction, which usually occurs in the last trimester of pregnancy. However preeclampsia rarely occurs within 48 h of postpartum. In this report, we present the case of a 20-year-old patient with oliguria, proteinuria, edema, and hypertension who was diagnosed with preeclampsia starting at the 35th week of her first pregnancy. Acute kidney failure developed in the postpartum period after emergency cesarian delivery. Crescentic and diffuse LN was revealed by renal biopsy. While SLE is a risk factor for preeclampsia, LN should be considered in kidney failure in the third trimester or postpartum period.

🔖

Cite This Article

EROĞLU, E., DEDE, M. Ç., KOÇYİĞİT, İ., SİPAHİOĞLU, M. H., AKGÜN, H., TOKGÖZ, B., OYMAK, O. (2020). Lupus Nephritis Presenting with Preeclampsia. Turkish journal of nephrology (Online), Cilt: 29 - Sayı: 1, 84–88. https://ajindex.com/articles/374857

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Muehrcke RC, Kark RM, Pirani CL, Pollak VE. Lupus nephritis: a clinical and pathological study based on renal biopsies. Medicine (Baltimore) 1957; 36: 1-145. [CrossRef] 2. Murrah FA. Lupus erythematosus in pregnancy. J Obstet Gynaecol Br Emp 1958; 65: 401-8. [CrossRef] 3. Garsenstein M, PollakVE, Kark RM. Systemic lupus erythematosus and pregnancy. New Engl J Med 1962; 267: 165-9. [CrossRef] 4. Estes D, Larson DL. Systemic lupus erithematosus and pregnancy. Clin Obstet Gynecol 1965; 8: 307-21. [CrossRef] 5. Bear RA. Pregnancy in patients with renal disease: A study of 44 cases. Obstet Gynecol 1976; 48: 13-26. 6. Houser MT, Fish AJ, Tagats GE, Williams PP, Michael AF. Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol 1980; 138: 409-13. [CrossRef] 7. Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL. Preeclampsia and antioxidant nutrients: Decreased plasma levels of reduced ascorbic acid, a-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol 1994; 171: 150-7. [CrossRef] 8. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-4. [CrossRef] 9. Wang Y, Walsh SW, Guo J, Zhang J. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol 1991; 165: 1695-700. [CrossRef] 10. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205. [CrossRef] 11. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 26: 1871-9. [CrossRef] 12. Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A, et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988; 34: 511-7. [CrossRef